Metabolic response assessment and PET-guided treatment of esophageal cancer
- 1 February 2020
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (2), 163-164
- https://doi.org/10.1016/j.annonc.2019.11.008
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialThe Lancet, 2019
- Oesophageal cancerNature Reviews Disease Primers, 2017
- Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy TrialJournal of Clinical Oncology, 2016
- Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric JunctionJournal of Clinical Oncology, 2014
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerThe New England Journal of Medicine, 2012
- Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal CancerJournal of Clinical Oncology, 2009
- PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trialThe Lancet Oncology, 2007
- Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric JunctionJournal of Clinical Oncology, 2006
- Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic ImagingJournal of Clinical Oncology, 2001